AKT1 and urinary bladder cancer: While NVP-BEZ235 by itself showed only a limited antitumor effect in bladder cancer cells, it synergistically potentiated cisplatin-mediated apoptosis and cell cycle arrest without any paradoxical activation of Akt in cisplatin-resistant human bladder cancer cells.